Megan M Kaneda
Overview
Explore the profile of Megan M Kaneda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishnamoorthy M, Seelige R, Brown C, Chau N, Nielsen Viller N, Johnson L, et al.
Front Immunol
. 2025 Mar;
16:1518787.
PMID: 40078999
Introduction: CD47 is highly expressed on cancer cells and triggers an anti-phagocytic "don't eat me" signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages. While...
2.
Christo S, McDonald K, Burn T, Kurd N, Stanfield J, Kaneda M, et al.
Clin Transl Immunology
. 2024 Nov;
13(11):e70014.
PMID: 39584189
Objectives: Bispecific antibodies targeting CD47 and PD-L1 (CD47 × PD-L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti-CD47-mediated toxicity, the effect of combined innate...
3.
Schmid M, Kang S, Chen H, Paradise M, Ghebremedhin A, Kaneda M, et al.
Nat Commun
. 2022 Apr;
13(1):1768.
PMID: 35365657
Myeloid cells play key roles in cancer immune suppression and tumor progression. In response to tumor derived factors, circulating monocytes and granulocytes extravasate into the tumor parenchyma where they stimulate...
4.
Li J, Kaneda M, Ma J, Li M, Shepard R, Patel K, et al.
Proc Natl Acad Sci U S A
. 2021 Apr;
118(16).
PMID: 33846242
Precision medicine in oncology leverages clinical observations of exceptional response. Toward an understanding of the molecular features that define this response, we applied an integrated, multiplatform analysis of RNA profiles...
5.
Schmid M, Khan S, Kaneda M, Pathria P, Shepard R, Louis T, et al.
Nat Commun
. 2018 Dec;
9(1):5379.
PMID: 30568188
Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins,...
6.
Foubert P, Kaneda M, Varner J
Cancer Immunol Res
. 2017 Oct;
5(11):957-968.
PMID: 28963139
Immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) accumulate in tumors where they inhibit T cell-mediated antitumor immune responses and promote tumor progression. Myeloid cell PI3Kγ plays a role...
7.
Sato-Kaneko F, Yao S, Ahmadi A, Zhang S, Hosoya T, Kaneda M, et al.
JCI Insight
. 2017 Sep;
2(18).
PMID: 28931759
Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not benefit from these agents. To...
8.
Kaneda M, Messer K, Ralainirina N, Li H, Leem C, Gorjestani S, et al.
Nature
. 2016 Dec;
542(7639):124.
PMID: 27974794
No abstract available.
9.
Kaneda M, Messer K, Ralainirina N, Li H, Leem C, Gorjestani S, et al.
Nature
. 2016 Nov;
539(7629):437-442.
PMID: 27642729
Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer. In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages...
10.
Kaneda M, Cappello P, Nguyen A, Ralainirina N, Hardamon C, Foubert P, et al.
Cancer Discov
. 2016 May;
6(8):870-85.
PMID: 27179037
Unlabelled: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a low 5-year survival rate, yet new immunotherapeutic modalities may offer hope for this and other intractable cancers. Here, we...